 | • レポートコード：20QY06-08281 • 出版社/出版日：QYResearch / 2020年6月1日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、145ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品・医療 |
| Single User | ￥592,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥888,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,184,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社の当調査資料では、表皮水疱症のグローバル市場について種類別（EB-201、FCX-007、ICX-RHY、INM-750、その他）、用途別（クリニック、病院、その他）、地域別（北米、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。 ・表皮水疱症市場の概要 ・世界の主要地域別表皮水疱症市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界の表皮水疱症市場規模2015-2026：種類別（EB-201、FCX-007、ICX-RHY、INM-750、その他） ・世界の表皮水疱症市場規模2015-2026：用途別（クリニック、病院、その他） ・表皮水疱症の北米市場規模2015-2020 ・表皮水疱症のヨーロッパ市場規模2015-2020 ・表皮水疱症の中国市場規模2015-2020 ・表皮水疱症の日本市場規模2015-2020 ・表皮水疱症の東南アジア市場規模2015-2020 ・表皮水疱症のインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 （Birken AG、Fibrocell Science, Inc.、GlaxoSmithKline Plc、InMed Pharmaceuticals Inc.、Karus Therapeutics Limited、ProQR Therapeutics N.V.、RegeneRx Biopharmaceuticals, Inc.、Scioderm, Inc.、Stratatech Corporation、TWi Pharmaceuticals, Inc.、WAVE Life Sciences Ltd.） ・表皮水疱症の製造コスト分析 ・販売チャネル、流通業者、顧客 ・表皮水疱症の市場動向・機会・課題 ・調査の結論 |
Market Analysis and Insights: Global Epidermolysis Bullosa Therapeutics Market
The global Epidermolysis Bullosa Therapeutics market was valued at US$ xx million in 2019 and will reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2020-2026.
Global Epidermolysis Bullosa Therapeutics Scope and Market Size
The global Epidermolysis Bullosa Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Epidermolysis Bullosa Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Epidermolysis Bullosa Therapeutics market is segmented into
EB-201
FCX-007
ICX-RHY
INM-750
Others
Segment by Application, the Epidermolysis Bullosa Therapeutics market is segmented into
Clinic
Hospital
Others
The Epidermolysis Bullosa Therapeutics market is analysed and market size information is provided by regions (countries). Segment by Application, the Epidermolysis Bullosa Therapeutics market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Epidermolysis Bullosa Therapeutics Market Share Analysis
Epidermolysis Bullosa Therapeutics market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Epidermolysis Bullosa Therapeutics business, the date to enter into the Epidermolysis Bullosa Therapeutics market, Epidermolysis Bullosa Therapeutics product introduction, recent developments, etc.
The major vendors covered:
Birken AG
Fibrocell Science, Inc.
GlaxoSmithKline Plc
InMed Pharmaceuticals Inc.
Karus Therapeutics Limited
ProQR Therapeutics N.V.
RegeneRx Biopharmaceuticals, Inc.
Scioderm, Inc.
Stratatech Corporation
TWi Pharmaceuticals, Inc.
WAVE Life Sciences Ltd.
Table of Contents
1 Epidermolysis Bullosa Therapeutics Market Overview
1.1 Epidermolysis Bullosa Therapeutics Product Scope
1.2 Epidermolysis Bullosa Therapeutics Segment by Type
1.2.1 Global Epidermolysis Bullosa Therapeutics Sales by Type (2020-2026)
1.2.2 EB-201
1.2.3 FCX-007
1.2.4 ICX-RHY
1.2.5 INM-750
1.2.6 Others
1.3 Epidermolysis Bullosa Therapeutics Segment by Application
1.3.1 Global Epidermolysis Bullosa Therapeutics Sales Comparison by Application (2020-2026)
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Epidermolysis Bullosa Therapeutics Market Estimates and Forecasts (2015-2026)
1.4.1 Global Epidermolysis Bullosa Therapeutics Sales Growth Rate (2015-2026)
1.4.2 Global Epidermolysis Bullosa Therapeutics Revenue and Growth Rate (2015-2026)
1.4.3 Global Epidermolysis Bullosa Therapeutics Price Trends (2015-2026)
2 Epidermolysis Bullosa Therapeutics Estimate and Forecast by Region
2.1 Global Epidermolysis Bullosa Therapeutics Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Epidermolysis Bullosa Therapeutics Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Epidermolysis Bullosa Therapeutics Sales Market Share by Region (2015-2020)
2.2.2 Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Region (2015-2020)
2.3 Global Epidermolysis Bullosa Therapeutics Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Epidermolysis Bullosa Therapeutics Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Epidermolysis Bullosa Therapeutics Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Epidermolysis Bullosa Therapeutics Estimates and Projections (2015-2026)
2.4.2 Europe Epidermolysis Bullosa Therapeutics Estimates and Projections (2015-2026)
2.4.3 China Epidermolysis Bullosa Therapeutics Estimates and Projections (2015-2026)
2.4.4 Japan Epidermolysis Bullosa Therapeutics Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Epidermolysis Bullosa Therapeutics Estimates and Projections (2015-2026)
2.4.6 India Epidermolysis Bullosa Therapeutics Estimates and Projections (2015-2026)
3 Global Epidermolysis Bullosa Therapeutics Competition Landscape by Players
3.1 Global Top Epidermolysis Bullosa Therapeutics Players by Sales (2015-2020)
3.2 Global Top Epidermolysis Bullosa Therapeutics Players by Revenue (2015-2020)
3.3 Global Epidermolysis Bullosa Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Epidermolysis Bullosa Therapeutics as of 2019)
3.4 Global Epidermolysis Bullosa Therapeutics Average Price by Company (2015-2020)
3.5 Manufacturers Epidermolysis Bullosa Therapeutics Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Epidermolysis Bullosa Therapeutics Players (Opinion Leaders)
4 Global Epidermolysis Bullosa Therapeutics Market Size by Type
4.1 Global Epidermolysis Bullosa Therapeutics Historic Market Review by Type (2015-2020)
4.1.1 Global Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2015-2020)
4.1.2 Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Type (2015-2020)
4.1.3 Global Epidermolysis Bullosa Therapeutics Price by Type (2014-2020)
4.2 Global Epidermolysis Bullosa Therapeutics Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Epidermolysis Bullosa Therapeutics Sales Forecast by Type (2021-2026)
4.2.2 Global Epidermolysis Bullosa Therapeutics Revenue Forecast by Type (2021-2026)
4.2.3 Global Epidermolysis Bullosa Therapeutics Price Forecast by Type (2021-2026)
5 Global Epidermolysis Bullosa Therapeutics Market Size by Application
5.1 Global Epidermolysis Bullosa Therapeutics Historic Market Review by Application (2015-2020)
5.1.1 Global Epidermolysis Bullosa Therapeutics Sales Market Share by Application (2015-2020)
5.1.2 Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Application (2015-2020)
5.1.3 Global Epidermolysis Bullosa Therapeutics Price by Application (2015-2020)
5.2 Global Epidermolysis Bullosa Therapeutics Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Epidermolysis Bullosa Therapeutics Sales Forecast by Application (2021-2026)
5.2.2 Global Epidermolysis Bullosa Therapeutics Revenue Forecast by Application (2021-2026)
5.2.3 Global Epidermolysis Bullosa Therapeutics Price Forecast by Application (2021-2026)
3 North America Epidermolysis Bullosa Therapeutics Market Facts & Figures
3.2 North America Epidermolysis Bullosa Therapeutics Sales Market Share by Company (2015-2020)
3.3 North America Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2015-2020)
3.4 North America Epidermolysis Bullosa Therapeutics Sales Market Share by Application (2015-2020)
4 Europe Epidermolysis Bullosa Therapeutics Market Facts & Figures
4.2 Europe Epidermolysis Bullosa Therapeutics Sales Market Share by Company (2015-2020)
4.3 Europe Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2015-2020)
4.4 Europe Epidermolysis Bullosa Therapeutics Sales Market Share by Application (2015-2020)
5 China Epidermolysis Bullosa Therapeutics Market Facts & Figures
5.2 China Epidermolysis Bullosa Therapeutics Sales Market Share by Company (2015-2020)
5.3 China Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2015-2020)
5.4 China Epidermolysis Bullosa Therapeutics Sales Market Share by Application (2015-2020)
6 Japan Epidermolysis Bullosa Therapeutics Market Facts & Figures
6.2 Japan Epidermolysis Bullosa Therapeutics Sales Market Share by Company (2015-2020)
6.3 Japan Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2015-2020)
6.4 Japan Epidermolysis Bullosa Therapeutics Sales Market Share by Application (2015-2020)
7 Southeast Asia Epidermolysis Bullosa Therapeutics Market Facts & Figures
7.2 Southeast Asia Epidermolysis Bullosa Therapeutics Sales Market Share by Company (2015-2020)
7.3 Southeast Asia Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2015-2020)
7.4 Southeast Asia Epidermolysis Bullosa Therapeutics Sales Market Share by Application (2015-2020)
8 India Epidermolysis Bullosa Therapeutics Market Facts & Figures
8.2 India Epidermolysis Bullosa Therapeutics Sales Market Share by Company (2015-2020)
8.3 India Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2015-2020)
8.4 India Epidermolysis Bullosa Therapeutics Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Epidermolysis Bullosa Therapeutics Business
12.1 Birken AG
12.1.1 Birken AG Epidermolysis Bullosa Therapeutics Corporation Information
12.1.2 Birken AG Epidermolysis Bullosa Therapeutics Business Overview and Total Revenue
12.1.3 Birken AG Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Birken AG Epidermolysis Bullosa Therapeutics Products Offered
12.1.5 Birken AG Recent Development
12.2 Fibrocell Science, Inc.
12.2.1 Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Corporation Information
12.2.2 Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Business Overview and Total Revenue
12.2.3 Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Products Offered
12.2.5 Fibrocell Science, Inc. Recent Development
12.3 GlaxoSmithKline Plc
12.3.1 GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Corporation Information
12.3.2 GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Business Overview and Total Revenue
12.3.3 GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2015-2020)
12.3.4 GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Products Offered
12.3.5 GlaxoSmithKline Plc Recent Development
12.4 InMed Pharmaceuticals Inc.
12.4.1 InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Corporation Information
12.4.2 InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Business Overview and Total Revenue
12.4.3 InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2015-2020)
12.4.4 InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Products Offered
12.4.5 InMed Pharmaceuticals Inc. Recent Development
12.5 Karus Therapeutics Limited
12.5.1 Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Corporation Information
12.5.2 Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Business Overview and Total Revenue
12.5.3 Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Products Offered
12.5.5 Karus Therapeutics Limited Recent Development
12.6 ProQR Therapeutics N.V.
12.6.1 ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Corporation Information
12.6.2 ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Business Overview and Total Revenue
12.6.3 ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2015-2020)
12.6.4 ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Products Offered
12.6.5 ProQR Therapeutics N.V. Recent Development
12.7 RegeneRx Biopharmaceuticals, Inc.
12.7.1 RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Corporation Information
12.7.2 RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Business Overview and Total Revenue
12.7.3 RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2015-2020)
12.7.4 RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Products Offered
12.7.5 RegeneRx Biopharmaceuticals, Inc. Recent Development
12.8 Scioderm, Inc.
12.8.1 Scioderm, Inc. Epidermolysis Bullosa Therapeutics Corporation Information
12.8.2 Scioderm, Inc. Epidermolysis Bullosa Therapeutics Business Overview and Total Revenue
12.8.3 Scioderm, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Scioderm, Inc. Epidermolysis Bullosa Therapeutics Products Offered
12.8.5 Scioderm, Inc. Recent Development
12.9 Stratatech Corporation
12.9.1 Stratatech Corporation Epidermolysis Bullosa Therapeutics Corporation Information
12.9.2 Stratatech Corporation Epidermolysis Bullosa Therapeutics Business Overview and Total Revenue
12.9.3 Stratatech Corporation Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2015-2020)
12.9.4 Stratatech Corporation Epidermolysis Bullosa Therapeutics Products Offered
12.9.5 Stratatech Corporation Recent Development
12.10 TWi Pharmaceuticals, Inc.
12.10.1 TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Corporation Information
12.10.2 TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Business Overview and Total Revenue
12.10.3 TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2015-2020)
12.10.4 TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Products Offered
12.10.5 TWi Pharmaceuticals, Inc. Recent Development
12.11 WAVE Life Sciences Ltd.
12.11.1 WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Corporation Information
12.11.2 WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Business Overview and Total Revenue
12.11.3 WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2015-2020)
12.11.4 WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Products Offered
12.11.5 WAVE Life Sciences Ltd. Recent Development
13 Epidermolysis Bullosa Therapeutics Manufacturing Cost Analysis
13.1 Epidermolysis Bullosa Therapeutics Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Epidermolysis Bullosa Therapeutics
13.4 Epidermolysis Bullosa Therapeutics Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Epidermolysis Bullosa Therapeutics Distributors List
14.3 Epidermolysis Bullosa Therapeutics Customers
15 Market Dynamics
15.1 Market Trends
15.2 Opportunities and Drivers
15.3 Challenges
15.4 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global Epidermolysis Bullosa Therapeutics Sales (K Pcs) Growth Rate by Type (2020-2026)
Table 2. Global Epidermolysis Bullosa Therapeutics Sales (K Pcs) Comparison by Application (2020-2026)
Table 3. Global Market Epidermolysis Bullosa Therapeutics Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 4. Global Epidermolysis Bullosa Therapeutics Sales (K Pcs) by Region (2015-2020)
Table 5. Global Epidermolysis Bullosa Therapeutics Sales Market Share by Region (2015-2020)
Table 6. Global Epidermolysis Bullosa Therapeutics Revenue (US$ Million) Market Share by Region (2015-2020))
Table 7. Global Epidermolysis Bullosa Therapeutics Revenue Share by Region (2015-2020)
Table 8. Global Epidermolysis Bullosa Therapeutics Sales (K Pcs) Forecast by Region (2021-2026)
Table 9. Global Epidermolysis Bullosa Therapeutics Sales Market Share Forecast by Region (2021-2026)
Table 10. Global Epidermolysis Bullosa Therapeutics Revenue (US$ Million) Forecast by Region (2021-2026)
Table 11. Global Epidermolysis Bullosa Therapeutics Revenue Share Forecast by Region (2021-2026)
Table 12. Global Epidermolysis Bullosa Therapeutics (K Pcs) of Key Companies (2015-2020)
Table 13. Global Epidermolysis Bullosa Therapeutics Sales Share by Company (2015-2020)
Table 14. Global Epidermolysis Bullosa Therapeutics Revenue (US$ Million) by Company (2015-2020)
Table 15. Global Epidermolysis Bullosa Therapeutics Revenue Share by Company (2015-2020)
Table 16. Global Epidermolysis Bullosa Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Epidermolysis Bullosa Therapeutics as of 2019)
Table 17. Global Epidermolysis Bullosa Therapeutics Average Price (USD/Pcs) of Key Company (2015-2020)
Table 18. Manufacturers Epidermolysis Bullosa Therapeutics Manufacturing Sites and Area Served
Table 19. Manufacturers Epidermolysis Bullosa Therapeutics Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Main Points Interviewed from Key Epidermolysis Bullosa Therapeutics Players
Table 22. Global Epidermolysis Bullosa Therapeutics Sales (K Pcs) by Type (2015-2020)
Table 23. Global Epidermolysis Bullosa Therapeutics Sales Share by Type (2015-2020)
Table 24. Global Epidermolysis Bullosa Therapeutics Revenue (US$ Million) Market Share by Type (2015-2020)
Table 25. Global Epidermolysis Bullosa Therapeutics Price (K Pcs) by Type (2015-2020)
Table 26. Global Epidermolysis Bullosa Therapeutics Sales Share by Type (2021-2026)
Table 27. Global Epidermolysis Bullosa Therapeutics Revenue (US$ Million) Market Share by Type (2021-2026)
Table 28. Global Epidermolysis Bullosa Therapeutics Revenue Share by Type (2021-2026)
Table 29. Global Epidermolysis Bullosa Therapeutics Price (K Pcs) by Type (2021-2026)
Table 30. Global Epidermolysis Bullosa Therapeutics Sales (K Pcs) by Application (2015-2020)
Table 31. Global Epidermolysis Bullosa Therapeutics Sales Share by Application (2015-2020)
Table 32. Global Epidermolysis Bullosa Therapeutics Revenue (US$ Million) Market Share by Application (2015-2020)
Table 33. Global Epidermolysis Bullosa Therapeutics Price (K Pcs) by Application (2015-2020)
Table 34. Global Epidermolysis Bullosa Therapeutics Sales (K Pcs) by Application (2021-2026)
Table 35. Global Epidermolysis Bullosa Therapeutics Sales Share by Application (2021-2026)
Table 36. Global Epidermolysis Bullosa Therapeutics Revenue (US$ Million) Market Share by Application (2021-2026)
Table 37. Global Epidermolysis Bullosa Therapeutics Revenue Share by Application (2021-2026)
Table 38. Global Epidermolysis Bullosa Therapeutics Price (K Pcs) by Application (2021-2026)
Table 39. United States Epidermolysis Bullosa Therapeutics Sales (K Pcs) by Company (2015-2020)
Table 40. United States Epidermolysis Bullosa Therapeutics Sales Market Share by Company (2015-2020)
Table 41. United States Epidermolysis Bullosa Therapeutics Sales (K Pcs) by Type (2015-2020)
Table 42. United States Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2015-2020)
Table 43. United States Epidermolysis Bullosa Therapeutics Sales (K Pcs) by Application (2015-2020)
Table 44. United States Epidermolysis Bullosa Therapeutics Sales Market Share by Application (2015-2020)
Table 45. Europe Epidermolysis Bullosa Therapeutics Sales (K Pcs) by Company (2015-2020)
Table 46. Europe Epidermolysis Bullosa Therapeutics Sales Market Share by Company (2015-2020)
Table 47. Europe Epidermolysis Bullosa Therapeutics Sales (K Pcs) by Type (2015-2020)
Table 48. Europe Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2015-2020)
Table 49. Europe Epidermolysis Bullosa Therapeutics Sales (K Pcs) by Application (2015-2020)
Table 50. Europe Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2015-2020)
Table 51. China Epidermolysis Bullosa Therapeutics Sales (K Pcs) by Company (2015-2020)
Table 52. China Epidermolysis Bullosa Therapeutics Sales Market Share by Company (2015-2020)
Table 53. China Epidermolysis Bullosa Therapeutics Sales (K Pcs) by Type (2015-2020)
Table 54. China Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2015-2020)
Table 55. China Epidermolysis Bullosa Therapeutics Sales (K Pcs) by Application (2015-2020)
Table 56. China Epidermolysis Bullosa Therapeutics Sales Market Share by Application (2015-2020)
Table 57. Japan Epidermolysis Bullosa Therapeutics Sales (K Pcs) by Company (2015-2020)
Table 58. Japan Epidermolysis Bullosa Therapeutics Sales Market Share by Company (2015-2020)
Table 59. Japan Epidermolysis Bullosa Therapeutics Sales (K Pcs) by Type (2015-2020)
Table 60. Japan Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2015-2020)
Table 61. Japan Epidermolysis Bullosa Therapeutics Sales (K Pcs) by Application (2015-2020)
Table 62. Japan Epidermolysis Bullosa Therapeutics Sales Market Share by Application (2015-2020)
Table 63. Southeast Asia Epidermolysis Bullosa Therapeutics Sales (K Pcs) by Company (2015-2020)
Table 64. Southeast Asia Epidermolysis Bullosa Therapeutics Sales Market Share by Company (2015-2020)
Table 65. Southeast Asia Epidermolysis Bullosa Therapeutics Sales (K Pcs) by Type (2015-2020)
Table 66. Southeast Asia Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2015-2020)
Table 67. Southeast Asia Epidermolysis Bullosa Therapeutics Sales (K Pcs) by Type (2015-2020)
Table 68. Southeast Asia Epidermolysis Bullosa Therapeutics Sales Market Share by Application (2015-2020)
Table 69. India Epidermolysis Bullosa Therapeutics Sales (K Pcs) by Company (2015-2020)
Table 70. India Epidermolysis Bullosa Therapeutics Sales Market Share by Company (2015-2020)
Table 71. India Epidermolysis Bullosa Therapeutics Sales (K Pcs) by Type (2015-2020)
Table 72. India Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2015-2020)
Table 73. India Epidermolysis Bullosa Therapeutics Sales (K Pcs) by Application (2015-2020)
Table 74. India Epidermolysis Bullosa Therapeutics Sales Market Share by Application (2015-2020)
Table 75. Birken AG Corporation Information
Table 76. Birken AG Description and Business Overview
Table 77. Birken AG Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 78. Birken AG Epidermolysis Bullosa Therapeutics Product
Table 79. Birken AG Recent Development
Table 80. Fibrocell Science, Inc. Corporation Information
Table 81. Fibrocell Science, Inc. Description and Business Overview
Table 82. Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 83. Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Product
Table 84. Fibrocell Science, Inc. Recent Development
Table 85. GlaxoSmithKline Plc Corporation Information
Table 86. GlaxoSmithKline Plc Description and Business Overview
Table 87. GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 88. GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Product
Table 89. GlaxoSmithKline Plc Recent Development
Table 90. InMed Pharmaceuticals Inc. Corporation Information
Table 91. InMed Pharmaceuticals Inc. Description and Business Overview
Table 92. InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 93. InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Product
Table 94. InMed Pharmaceuticals Inc. Recent Development
Table 95. Karus Therapeutics Limited Corporation Information
Table 96. Karus Therapeutics Limited Description and Business Overview
Table 97. Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 98. Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Product
Table 99. Karus Therapeutics Limited Recent Development
Table 100. ProQR Therapeutics N.V. Corporation Information
Table 101. ProQR Therapeutics N.V. Description and Business Overview
Table 102. ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 103. ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Product
Table 104. ProQR Therapeutics N.V. Recent Development
Table 105. RegeneRx Biopharmaceuticals, Inc. Corporation Information
Table 106. RegeneRx Biopharmaceuticals, Inc. Description and Business Overview
Table 107. RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 108. RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Product
Table 109. RegeneRx Biopharmaceuticals, Inc. Recent Development
Table 110. Scioderm, Inc. Corporation Information
Table 111. Scioderm, Inc. Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 112. Scioderm, Inc. Description and Business Overview
Table 113. Scioderm, Inc. Epidermolysis Bullosa Therapeutics Product
Table 114. Scioderm, Inc. Recent Development
Table 115. Stratatech Corporation Corporation Information
Table 116. Stratatech Corporation Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 117. Stratatech Corporation Description and Business Overview
Table 118. Stratatech Corporation Epidermolysis Bullosa Therapeutics Product
Table 119. Stratatech Corporation Recent Development
Table 120. TWi Pharmaceuticals, Inc. Corporation Information
Table 121. TWi Pharmaceuticals, Inc. Description and Business Overview
Table 122. TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 123. TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Product
Table 124. TWi Pharmaceuticals, Inc. Recent Development
Table 125. WAVE Life Sciences Ltd. Corporation Information
Table 126. WAVE Life Sciences Ltd. Description and Business Overview
Table 127. WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 128. WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Product
Table 129. WAVE Life Sciences Ltd. Recent Development
Table 130. Production Base and Market Concentration Rate of Raw Material
Table 131. Key Suppliers of Raw Materials
Table 132. Epidermolysis Bullosa Therapeutics Distributors List
Table 133. Epidermolysis Bullosa Therapeutics Customers List
Table 134. Market Key Trends
Table 135. Key Opportunities and Drivers: Impact Analysis (2020-2026)
Table 136. Key Challenges
Table 137. Research Programs/Design for This Report
Table 138. Key Data Information from Secondary Sources
Table 139. Key Data Information from Primary Sources
List of Figures
Figure 1. Epidermolysis Bullosa Therapeutics Product Picture
Figure 2. Global Epidermolysis Bullosa Therapeutics Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Epidermolysis Bullosa Therapeutics Market Share by Application in 2020 & 2026
Figure 6. Clinic Examples
Figure 7. Hospital Examples
Figure 8. Others Examples
Figure 9. Global Epidermolysis Bullosa Therapeutics Sales (K Pcs) Growth Rate (2015-2026)
Figure 10. Global Epidermolysis Bullosa Therapeutics Revenue (US$ Million) Growth Rate (2015-2026)
Figure 11. Global Epidermolysis Bullosa Therapeutics Price Trends Growth Rate (2015-2026) (USD/Pcs)
Figure 12. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Region: 2015 VS 2020
Figure 13. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Region: 2021 VS 2026
Figure 14. United States Epidermolysis Bullosa Therapeutics Revenue (Million USD) Growth Rate (2015-2026)
Figure 15. United States Epidermolysis Bullosa Therapeutics Sales (K Pcs) Growth Rate (2015-2026)
Figure 16. Europe Epidermolysis Bullosa Therapeutics Revenue (Million USD) Growth Rate (2015-2026)
Figure 17. Europe Epidermolysis Bullosa Therapeutics Sales (Million USD) Growth Rate (2015-2026)
Figure 18. China Epidermolysis Bullosa Therapeutics Revenue (Million USD) Growth Rate (2015-2026)
Figure 19. China Epidermolysis Bullosa Therapeutics Sales (Million USD) and Growth Rate (2015-2026)
Figure 20. Japan Epidermolysis Bullosa Therapeutics Revenue (Million USD) Growth Rate (2015-2026)
Figure 21. Japan Epidermolysis Bullosa Therapeutics Sales (Million USD) Growth Rate (2015-2026)
Figure 22. Southeast Asia Epidermolysis Bullosa Therapeutics Revenue (Million USD) Growth Rate (2015-2026)
Figure 23. Southeast Asia Epidermolysis Bullosa Therapeutics Sales (Million USD) Growth Rate (2015-2026)
Figure 24. India Epidermolysis Bullosa Therapeutics Revenue (Million USD) Growth Rate (2015-2026)
Figure 25. India Epidermolysis Bullosa Therapeutics Sales (Million USD) Growth Rate (2015-2026)
Figure 26. Global 5 Largest Epidermolysis Bullosa Therapeutics Players Market Share by Revenue in Epidermolysis Bullosa Therapeutics 2015 & 2019
Figure 27. Epidermolysis Bullosa Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 28. Global Epidermolysis Bullosa Therapeutics Revenue Share by Type (2015-2020)
Figure 29. Global Epidermolysis Bullosa Therapeutics Revenue Growth Rate by Type in 2015 & 2019
Figure 30. Global Epidermolysis Bullosa Therapeutics Revenue Share by Application (2015-2020)
Figure 31. Global Epidermolysis Bullosa Therapeutics Revenue Growth Rate by Application in 2015 & 2019
Figure 32. United States Epidermolysis Bullosa Therapeutics Sales Market Share by Type in 2019
Figure 33. United States Epidermolysis Bullosa Therapeutics Sales Market Share by Type in 2019
Figure 34. Europe Epidermolysis Bullosa Therapeutics Sales Market Share by Company in 2019
Figure 35. Europe Epidermolysis Bullosa Therapeutics Sales Market Share by Type in 2019
Figure 36. Europe Epidermolysis Bullosa Therapeutics Sales Market Share by Application in 2019
Figure 37. China Epidermolysis Bullosa Therapeutics Sales Market Share by Company in 2019
Figure 38. China Epidermolysis Bullosa Therapeutics Sales Market Share by Type in 2019
Figure 39. China Epidermolysis Bullosa Therapeutics Sales Market Share by Application in 2019
Figure 40. Japan Epidermolysis Bullosa Therapeutics Sales Market Share by Company in 2019
Figure 41. Japan Epidermolysis Bullosa Therapeutics Sales Market Share by Type in 2019
Figure 42. Japan Epidermolysis Bullosa Therapeutics Sales Market Share by Application in 2019
Figure 43. Southeast Asia Epidermolysis Bullosa Therapeutics Sales Market Share by Company in 2019
Figure 44. Southeast Asia Epidermolysis Bullosa Therapeutics Sales Market Share by Type in 2019
Figure 45. Southeast Asia Epidermolysis Bullosa Therapeutics Sales Market Share by Application in 2019
Figure 46. India Epidermolysis Bullosa Therapeutics Sales Market Share by Company in 2019
Figure 47. India Epidermolysis Bullosa Therapeutics Sales Market Share by Type in 2019
Figure 48. India Epidermolysis Bullosa Therapeutics Sales Market Share by Application in 2019
Figure 49. Birken AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. Fibrocell Science, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. GlaxoSmithKline Plc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. InMed Pharmaceuticals Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Karus Therapeutics Limited Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. ProQR Therapeutics N.V. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. RegeneRx Biopharmaceuticals, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Scioderm, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Stratatech Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. TWi Pharmaceuticals, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. WAVE Life Sciences Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. Key Raw Materials Price Trend
Figure 61. Manufacturing Cost Structure of Epidermolysis Bullosa Therapeutics
Figure 62. Manufacturing Process Analysis of Epidermolysis Bullosa Therapeutics
Figure 63. Epidermolysis Bullosa Therapeutics Industrial Chain Analysis
Figure 64. Channels of Distribution
Figure 65. Distributors Profiles
Figure 66. Porter's Five Forces Analysis
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
皮膚科治療装置の世界市場レポート2020 Market Analysis and Insights: Global Dermatology Therapeutics Devices Market The global Dermatology Therapeutics Devices market was valued at US$ xx million in 2019 and will reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2020-2026. Global Dermatology Therapeutics Devices Sc…- 口内乾燥症（ドライマウス）治療の世界市場レポート2020 Market Analysis and Insights: Global Xerostomia (Dry Mouth) Therapeutics Market The global Xerostomia (Dry Mouth) Therapeutics market was valued at US$ 556.9 million in 2019 and will reach US$ 657.9 million by the end of 2026, growing at a CAGR of 2.4% during 2020-2026. Global Xerostomia (Dry Mouth)…
- mRNAワクチンおよび治療薬の世界市場レポート2020 mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically wh…
- ペプチド治療剤の世界市場レポート2020 Peptides are short chains of amino acid monomers linked by peptide (amide) bonds, the covalent chemical bonds formed when the carboxyl group of one amino acid reacts with the amino group of another. North America is the largest consumption place, with a consumption market share nearly 60.9% in 2018.…
- 心不全治療の世界市場レポート2020 Heart failure (HF), often referred to as congestive heart failure (CHF), is when the heart is unable to pump sufficiently to maintain blood flow to meet the body's needs. Signs and symptoms commonly include shortness of breath, excessive tiredness, and leg swelling.The shortness of breath is usually…